Skip to main content

Neuromuscular and Mitochondrial Pathology

The group focuses on the study of pathogenic mechanisms of the mitochondrial diseases, either caused by mutations in nuclear DNA or mitochondrial DNA, associated to diverse neuromuscular syndromes. Specifically, our active research lines are devoted to the study of diseases caused by dysfunctional mitochondrial DNA replication and maintenance, and mitochondrial protein synthesis. We put special efforts on finding and testing potential therapy approaches through preclinical investigation using in vitro and in vivo models of these diseases. We are also working on developing new approaches for genetic diagnosis for these disorders, as well as on testing novel genetic variants for potential pathogenicity trough functional studies.

In addition, we are also working on the study of other metabolic neuromuscular disorders, such as the glycogenosis type V (McArdle Disease) and other muscle glycogenoses. This research line includes the coordination of the European patient registry EUROMAC. 

Publications

Effect of Resveratrol Content in Red Wine on Circulating Sex Hormone-Binding Globulin: Lessons from a Pilot Clinical Trial.

PMID: 35751841
Journal: MOLECULAR NUTRITION & FOOD RESEARCH
Year: 2022
Reference: Mol Nutr Food Res. 2022 Jun 25:e2200125. doi: 10.1002/mnfr.202200125.
Impact factor: 5.82
Publication type: Paper in international publication
Authors: Hernandez, Cristina; Simo, Rafael; Selva, David M; Torres-Torronteras, Javier; Ramos-Perez, Lorena; Brianso-Llort, Laura; Simo-Servat, Olga et al.
DOI: 10.1002/mnfr.202200125

ERM Complex, a Therapeutic Target for Vascular Leakage Induced by Diabetes.

PMID: 34042029
Journal: CURRENT MEDICINAL CHEMISTRY
Year: 2022
Reference: Curr Med Chem. 2022;29(12):2189-2199. doi: 10.2174/0929867328666210526114417.
Impact factor: 4.53
Publication type: Paper in international publication
Authors: Simo-Servat, Olga, Ramos, Hugo, Bogdanov, Patricia, Garcia-Ramirez, Marta, Huerta, Jordi, Hernandez, Cristina, Simo, Rafael et al.
DOI: 10.2174/0929867328666210526114417

Minimum Effective Dose of DPP-4 Inhibitors for Treating Early Stages of Diabetic Retinopathy in an Experimental Model.

PMID: 35203674
Journal: Biomedicines
Year: 2022
Reference: Biomedicines. 2022 Feb 16;10(2). pii: biomedicines10020465. doi: 10.3390/biomedicines10020465.
Impact factor: 6.081
Publication type: Paper in international publication
Authors: Hernandez, Cristina, Simo, Rafael, Huerta, Jordi, Bogdanov, Patricia, Ramos, Hugo, Valeri, Marta, Deas-Just, Anna et al.
DOI: 10.3390/biomedicines10020465

Blog

News

The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.

The newly developed analytical workflow could in the future be introduced as a comprehensive diagnostic test for patients with mitochondrial diseases.

Rates

Check the current rates of the Neuromuscular and Mitochondrial Pathology research group.